Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon (SWING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04107298
Recruitment Status : Not yet recruiting
First Posted : September 27, 2019
Last Update Posted : October 1, 2019
Sponsor:
Information provided by (Responsible Party):
SurModics, Inc.

Brief Summary:
To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Critical Lower Limb Ischemia Device: SUNDANCE™ Drug Coated Balloon Not Applicable

Detailed Description:
SWING is a prospective, multi-center, single-arm, feasibility study to assess the safety and performance of the Sundance™ drug coated balloon for the treatment of de novo or restenotic lesions in infra-popliteal Arteries. Approximately 35 subjects will be treated at up to 8 sites.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Single-Arm, Feasibility Study to Assess the Safety and Performance WIth the SUNDANCE™ DruG Coated Balloon for the Treatment of De Novo or Restenotic Lesions in Infra-Popliteal Arteries
Estimated Study Start Date : February 15, 2020
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : July 1, 2023

Arm Intervention/treatment
Experimental: SUNDANCE™ Drug Coated Balloon
SUNDANCE™ Drug Coated Balloon
Device: SUNDANCE™ Drug Coated Balloon
Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter




Primary Outcome Measures :
  1. Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death [ Time Frame: 30 Days ]
    MALE is defined as the composite of either major amputation or major re-intervention through 30 days of the index procedure. Major amputation is defined as limb amputation above the ankle. Major re-intervention is defined as the creation of new surgical bypass graft, the use of thrombectomy or thrombolysis, or major surgical graft revision such as a jump graft or an interposition graft.

  2. Primary Efficacy Endpoint: Rate of Late Lumen Loss (LLL) [ Time Frame: 6 Months ]
    LLL is assessed by quantitative vascular angiography (QVA). LLL is the difference between minimum lumen diameter (MLD) immediately after PTA and MLD at 6 months follow-up.


Secondary Outcome Measures :
  1. Rate of Device Success [ Time Frame: Acute/Periprocedural ]
    Successful delivery, balloon inflation, deflation and retrieval of the intact study device

  2. Rate of Technical Success [ Time Frame: Acute/Periprocedural ]
    Successful vascular access, completion of endovascular procedure and immediate achievement of ≤ 50% residual stenosis (by core lab-assessed quantitative vascular angiography) of the treated lesion on completion of angiography.

  3. Rate of Procedure Success [ Time Frame: Acute/Periprocedural ]
    Device Success or Technical Success and the absence of procedural complications.

  4. Rate of Restenosis [ Time Frame: 6 Months or prior ]
    Assessed by Transverse-view vessel area loss percentage (TVAL%) assessed by QVA. TVAL% of the target lesion at 6 months or prior to any clinically driven target lesion revascularization (CD-TLR) of the target lesion prior to 6 months.

  5. Number of Participants with Primary Patency [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Freedom from target vessel occlusion as determined by DUS and CD-TLR. CD-TLR is defined as any TLR of the target lesion associated with deterioration of Rutherford Class and/or increase in size of pre-existing wounds and/or occurrence of new wound(s), and lesion restenosis >50% determined by angiography.

  6. Major Adverse Event (MAE) rate [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Composite rate of all-cause death, target limb major amputation and CD-TLR.

  7. Amputation Free Survival [ Time Frame: 6 Months, 12 Months, 24 Months ]
    Rate of subjects not requiring major amputations

  8. Hemodynamic outcomes [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Change in ankle brachial index (ABI) and toe pressure from pre-procedure.

  9. Change in Rutherford-Becker Classification [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Change from pre-procedure

  10. EQ-5D [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]

    The EQ-5D is not an abbreviation. It is a quality of Life evaluation quantified as the change from pre-procedure to time points specified below. The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.

    The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'


  11. Walking Impairment Questionnaire (WIQ) [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Walking Capacity Assessment quantified as the change from pre-procedure to time points specified below.The questions characterize patients' self-reported degree of difficulty in walking a defined distance (5, 3, 2, 1, 1/2 city blocks, 50 ft. or around the home) and speed (running/jogging one block, walking one block quickly, walking one block at average speed, or walking one block slowly). These responses are ranked on a scale of 0 to 4, (0=unable to do, 4=no difficulty). Subscale scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Each score ranges from 0-100 with lower scores indicating lower performance. The overall score is the average of all 3 subscores.

  12. Vascular Quality of Life Questionnaire (VascuQol) [ Time Frame: 30 Days, 6 Months, 12 Months, 24 Months ]
    Quality of Life evaluation quantified as the change from pre-procedure to time points specified below. VascuQol is an instrument in which the participant is asked about their concerns, abilities, and activities. Overall values can range from 6 to 24, with a higher total sum representing better participant health.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Clinical Inclusion Criteria

  • Subject is ≥18 years.
  • Subject has target limb Rutherford classification 4 or 5. Rutherford classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (i.e., no more than 7 Rutherford class 3 subjects may be enrolled in the study).
  • Subject has provided written informed consent and is willing to comply with study follow-up requirements.

Clinical Exclusion Criteria

  • Subject has acute limb ischemia.
  • Subject underwent intervention involving the target vessel (not a proximal inflow vessel) within the previous 90 days.
  • Subject previously underwent PTA of the target lesion vessel using a DCB or DES.
  • Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure.
  • Subjects with heel gangrene, deep heel ulcers, osteomyelitis of tarsal or metatarsal bones (which extends beyond the metatarsal head immediately adjacent to the metatarso-phalangeal joint), and subjects with exposed vital structures (e.g., medial or lateral malleolus).
  • Subjects requiring pedal angioplasty.
  • Subjects that are non-ambulatory and confined to bed.
  • Women who are pregnant, breast-feeding or intend to become pregnant or men who intend to father children during the time of the study.
  • Subject has history of Class 3 (and above) congestive heart failure (CHF) in past 6 months.
  • Subject has life expectancy less than 12 months.
  • Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
  • Subject has known hypersensitivity to sirolimus
  • Subject has a known contraindication to the intended concomitant medications.
  • Subject is allergic to ALL antiplatelet treatments.
  • Subject has impaired renal function (i.e. serum creatinine level ≥2.5 mg/dL or ≥221 µmol/L).
  • Subject had major limb amputation on the affected side in last year or has planned major limb amputation.
  • Subject is receiving immunosuppressant therapy.
  • Subject has known or suspected active infection at the time of the index procedure.
  • Subject has platelet count <100,000/mm3 or >700,000/mm3.
  • Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure.
  • Subject is diagnosed with coagulopathy or other disorders which are contraindications for treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
  • Subject has history of stroke within the past 3 months.
  • Subject has a history of myocardial infarction within the past 30 days.
  • Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
  • Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol.
  • Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
  • Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure.
  • Subject had previous bypass surgery of the target lesion.
  • Subject had previously implanted stent in target lesion.
  • Subject had previous treatment of the target vessel with thrombolysis or surgery.
  • Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.

Angiographic Inclusion Criteria

  • The target lesion/vessel must meet all of the following angiographic criteria for the subject to participate in the trial:
  • De novo lesion(s) or non-stented restenotic lesion
  • Target lesion location starts at the P3 segment and terminates at 1cm above the ankle. Note: Isolated P3 lesion is not allowed. If a lesion starts in the P3 segment, it must continue into the infrapopliteal.
  • Target vessel diameter ≥2 mm and ≤4 mm, based on visual estimation.
  • Target lesion must have angiographic evidence of ≥70% stenosis by operator visual estimate.
  • Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion. Use of re-entry/crossing devices is not allowed. Crossing may be performed retrograde, but treatment must be performed antegrade.

Uncomplicated: Upon visual inspection, no occurrence of embolization, perforation, or occurrence of flow-limiting dissection.

  • Target lesion(s) must be ≤230 mm in total lesion(s) length by operator visual estimate. A maximum of two lesions may be treated. The two lesions may be in one infrapopliteal vessel or in two distinct infrapopliteal vessels. Note: Tandem lesions may be considered a single lesion if they are separated by ≤30 mm.
  • After pre-dilatation, the target lesion has ≤70% residual stenosis, absence of a flow limiting dissection (Grade D or greater) and treatable with available device matrix.
  • A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography.
  • At least one patent native outflow artery to the ankle or foot distal to the lesion being treated, free from significant stenosis (≥50% stenosis) as confirmed by angiography.

Angiographic Exclusion Criteria

  • Aneurysm in the target vessel or proximal inflow artery.
  • Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length ≥15 cm.
  • Significant stenosis (≥ 50%) in inflow lesion or occlusion in the ipsilateral iliac, SFA, popliteal arteries left untreated.
  • Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, or re-entry devices.
  • Significant target vessel tortuosity or other parameters prohibiting access to the target lesion.
  • Presence of thrombus in the target vessel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04107298


Contacts
Layout table for location contacts
Contact: Aaron Jacobson, DC, CCRP 651-366-2215 ajacobson@surmodics.com
Contact: Jessica Kleine 612-280-0208 jkleine@surmodics.com

Sponsors and Collaborators
SurModics, Inc.
Layout table for additonal information
Responsible Party: SurModics, Inc.
ClinicalTrials.gov Identifier: NCT04107298    
Other Study ID Numbers: SUR19-002
First Posted: September 27, 2019    Key Record Dates
Last Update Posted: October 1, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Ischemia
Pathologic Processes
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases